D09.3
Carcinoma in situ of thyroid and other endocrine glands
Clinical Classification Guidelines
Excludes Type 1
- carcinoma in situ of endocrine pancreas (D01.7)
- carcinoma in situ of ovary (D07.39)
- carcinoma in situ of testis (D07.69)
Medical Intelligence & Overview
Carcinoma in situ (CIS) of the thyroid and other endocrine glands is a preliminary or early form of cancer confined within the lining tissues of these glands. Being in situ means the abnormal cells have not yet invaded neighboring tissues or spread to other parts of the body. Recognizing this stage is crucial because it offers the potential for effective treatment and a more favorable prognosis. This condition involves abnormal cell growth that resembles cancer but has not yet demonstrated invasive properties, making it a vital focus for early diagnosis and intervention.
Causes & Symptoms
Clinical Causes: Genetic mutations affecting cell growth and division Environmental factors such as radiation exposure Inherited genetic predispositions Chronic inflammation or endocrine gland disorders Certain exposure to endocrine-disrupting chemicals
Key Symptoms: Often no noticeable symptoms in the early stages A palpable lump or swelling in the neck area Unexplained hoarseness or voice changes Difficulty swallowing or a sensation of a lump in the throat Persistent cough not related to respiratory infections
Diagnostic & Treatment
Diagnosis Path: Physical examination focusing on the neck and throat Ultrasound imaging of the thyroid and surrounding glands Fine-needle aspiration biopsy (FNA) to analyze abnormal cells Thyroid function tests to assess hormone levels Additional imaging or biopsy procedures as needed to confirm the diagnosis
Treatment Protocols: Surgical removal of the affected gland or part of it, such as a partial or total thyroidectomy Close monitoring with regular imaging and biopsies for watchful waiting in some cases Radioactive iodine therapy, sometimes used in specific situations Targeted therapies or hormone suppression, depending on the gland involved Follow-up care to detect any signs of progression or recurrence
Clinical Advice & FAQs
Billing Guidance
Is D09.3 a billable ICD-10 code?
Yes, D09.3 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D09.3?
Clinical documentation must specify the nature of Carcinoma in situ of thyroid and other endocrine glands and any associated comorbidities for accurate reporting.
Cite this Clinical Reference